Project Ambition

The MycoSynVac project aims at using cutting-edge synthetic biology methods to engineer Mycoplasma pneumoniae as a universal chassis for vaccination. We will (1) modify existing methods of genome transplantation used for Mycoplasma species, (2) develop serum-free medium for scale-up in bioreactors and (3) analyze how to bring the product to market after efficacy of the vaccine has been shown in animal studies, ultimately to fight Mycoplasma infections in farm animals.

 

  • Ethical Framework: a study of the benefits and risks of MycoSynVac products by the University of Copenhagen
  • 3rd MycoSynVac consortium meeting & the B∙Debate on Synthetic Biology

  • MYCOSYNVAC AT THE EUROPEAN MYCOPLASMA CONFERENCE

  • 2019 EMBO Course on Whole-Cell Modeling

  • Luis Garcia Morales’ impressions on the TRANSVAC training course on Adjuvants and Vaccine formulation

  • Luis Serrano receives the XII Francisco Cobos award